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Summary 
In previous studies, we observed that when rats were chronically 
treated with haloperidol, there was a significant increase of 
calmodulin activity in their striatal membranes. Calmodulin is known 
to modulate calcium-dependent protein phosphorylation in neural 
membranes. In the present study, we found that the total 
32p-incorporation in the striatal proteins from chronic 
haloperidol-treated rats was significantly increased in comparison to 
saline-treated rats. A majority of the phosphorylation was 
attributed to the calcium-mediated activity, since it could be 
blocked by a calcium chelating agent (EGTA). By using EGTA to 
inhibit phosphorylation, the results indicated that the 
haloperidol-treated rats had approximately 3.5-fold greater 
Ca++-dependent protein kinase activity than the saline-treated rats. 
Exogenous calcium alone was insufficient to stimulate phosphorylation 
in the haloperidol-treated rats to the same magnitude as in the 
saline-treated rats. Calmodulin may be required. ~2p-incorporation 
of two striatal proteins at molecular weight 40 and 52 kilodaltons 
were markedly stimulated by calcium. Cyclic AMP-mediated 
phosphorylation seemed to take only a small part in the alteration of 
total phosphorylation. Therefore, the increase of calmodulin 
activity and calcium-dependent phosphorylation appears to play a 
major role in the drug-induced dopamine receptor supersensitivity in 
rat striatum. 
A number of neurological syndromes (e.g. tardive dyskinesia) are developed 
as a consequence of chronic treatment with neuroleptic drugs. In rats 
chronically treated with haloperidol, a dopamine receptor antagonist, there is 
an increase of stereotypic behavior after challenges with dopaminergic receptor 
agonists (I). This alteration of behavioral manifestation has been associated 
with the increase of dopamine receptor binding sites (2) and the elevation of 
dopamine-sensitive adenylate cyclase activity (3) in the striatum. Most 
recently, we have also observed an increase of calmodulin (a calcium-binding 
protein) activity in the chronic haloperidol-treated rat striatal membranes 
(4). In the present study, we examined the effects of this chronic haloperidol 
treatment on calcium-mediated protein phosphorylation in rat striatal 
particulate preparations. 
Methods 
Animal treatment and striatal particulate preparation. Male, Sprague 
Dawley rats (120-150 g) were injected subcutaneously daily for 20 days with 
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either saline (0.2 ml) or haloperidol I mg/kg). Five days after the 
termination of treatment, the animals were sacrificed by decapitation. Striata 
from each animal were isolated and immediately homogenized in 9 volumes of 
ice-cold 50 mM Piperazine-N,N'-bis [2-ethane-sulfonic acid] (PIPES) buffer, pH 
7.0, containing 10 mM MgCI 2. The homogenate was centrifuged at 27,000 g for 20 
minutes at 4°C. The pellet was washed once and then resuspended in the same 
buffer for the use in phosphorylation assays. For determining 
calcium-dependent phosphorylation, 1.2 mM ethylene glycol bis-(B-aminoethyl 
ether)-N,N'-tetraacetic acid (EGTA) was included in the homogenizing and 
resuspending medium. 
Protein phosphorylation assays. Calcium-dependent protein phosphorylation 
in the striatal preparations from saline- or haloperidol-treated rats was 
measured in an assay medium (0.1 ml final volume) containing 50 mM PIPES 
buffer, pH 7.0, 10 mM MgC12, 0.1 mM dithiothreitol, 25 uM ATP (I uCi32p-ATP per 
assay) and 20 ~i of the striatal sample protein which was suspended in 1.2 mM 
EGTA. Hence the final concentration of EGTA in each assay was 0.24 mM. 
Protein content of each sample was determined by the method of Lowry, et al. 
(5). An equivalent amount of protein (80 ~g) from the striatum of the control 
and the drug-treated rats was used in each assay to initiate the reaction. The 
reactions were carried out at 30°C and terminated by pipetting 25 ul of the 
sample on to a Whatman 3MM filter disc which was washed immediately with 
ice-cold 10% trichioroacetic acid 3 times at 15 minute intervals. The filter 
was finally washed once with 95% ethanol, once with ether and then air-dried 
before the 32p-incorporated activity was counted by using liquid scintillation 
detection. 
Phosphoprotein analysis. Since total 32P-incorporation as determined by 
TCA precipitation method may also include its incorporation into phospholipids 
and acyl-phosphate bonds in the particulates, protein phosphorylation was also 
analyzed by using sodium dodecyl sulfate (SDS)-polyacrylamide gel 
electrophoresis (6) and autoradiography. The phosphorylation assay was carried 
out similarly as described above, except that the reactJon was terminated by 
adding 25 ~l of SDS-stop solution (2% SDS/62.5 mM Tris-HCl, pH 6.8/10% 
glycerol/5% 2-mercaptoethanol/0.O01% bromophenol blue) into the sample. The 
sample was boiled for 3 minutes before it was applied to a 5-15% 
SDS-polyacrylamide gradient gel. Six proteins with known molecular weights 
(phosphorylase b, bovine serum albumin, ovalbumin, carbonic anhydrase, soybean 
trypsin inhibitor and c-lactalbumin) were used as standards. After 
electrophoresis, the gel was stained, destained and dried accordingly (6). 
Autoradiography of the gel was performed by overlaying the gel with a Kodak 
x-ray film (XR-5) in the dark for 70 hours. Phosphorylated protein bands were 
also qualitatively scanned by using a densitometer (E-C Apparatus Corp.). 
Rat striatal particulate preparation contains high concentrations of 
calcium and calmoduiin (7). In order to quantitate the Ca ++ effect on protein 
phosphorylation in this preparation, a Ca++-EGTA buffer was used. The free 
calcium concentrations reported in this study were calculated according to 
Nanninga and Kempen (8) where the concentrations of EGTA, Mg, ATP and the 
buffer pH were taken into consideration. All data were calculated in terms of 
mean +S.E.M. Statistical analysis was performed by using the t test for group 
comparison. A P <0.05 was considered significant. 
Results 
Time course of protein phosphorylation. Initial experiments were 
performed to determine the time of incubation required for optimal 
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32p-incorporation in the rat striatal particulate preparation. A time 
dependent 32p-incorporation with a peak response at 2 minutes of incubation was 
observed in this preparation (FIG. I). This incubation period (2 min) was 
therefore chosen to examine and compare the protein phosphorylation in saline- 
and haloperidol-treated rats. A large component of protein phosphorylation in 
this preparation can be inhibited by pretreating the samples with a calcium 
chelating agent, EGTA (0.1 mM and 0.24 mM final assay concentration) (FIG. I). 
Therefore, this component represents the calcium-dependent phosphorylation 
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FIG. I 
Time course of 32p-incorporation in rat striatal particulate 
preparation. N=5. 3~-incorporation was time-dependent and an 
optimal incorporation was obtained after 2 minutes incubation. *A 
significant amount of 32p-incorporation was inhibited when the 
preparation was pretreated with EGTA. 
Effect of chronic haloperidol treatment on calcium-dependent 
phosphorylation. The total phosphorylation (without EGTA pretreatment) in the 
striatal proteins from five of the six haloperidol-treated rats was 
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significantly higher than the six saline-treated rats (TABLE I). When striatal 
particulates were prepared in the presence of 1.2 mM EGTA, phosphorylation in 
both saline- and haloperidol-treated rats was markedly inhibited (TABLE I). 
These results were analyzed by using a ratio of calcium-dependent 
phosphorylation (Total - in presence of EGTA) versus the calcium-independent 
phosphorylation (in presence of EGTA). These ratios revealed that the 
Ca++-dependent phosphorylation activity in the haloperidol-treated rats was 
about 3.5-fold greater than that in the saline-treated rats (TABLE I). 
TABLE I 
Calcium-Dependent Protein Phosphorylation in the Striatum 
of Chronically Treated Rats 
32p-Incorporation Ca++Dependent 
Treatment Activity Ratio 
Total EGTA a (TOTAL-EGTA) 
EGTA 
pmol/mg protein/2 min±S.E.M. 
Saline (N=6) 290 ± 20 100 ± 16 1.9 
Haloperidol (N=5) 370 + 21 b 46 + I0 b 7.0 b 
aThe striatum was pretreated with 1.2 mM EGTA. The final concentration of 
EGTA in the assay was 0.24 mM. Time of incubation was 2 minutes. 
bSignificantly different from saline control experiments (P< 0.05). 
In the EGTA pretreated particulate preparations, protein phosphorylation 
in bo'th saline- and haloperidol-treated rats could be stimulated by the 
exogenously added calcium in a concentration-dependent manner (FIG. 2). It 
should be noted, however, that protein phosphorylation in the 
haloperidol-treated rats could not be stimulated by calcium alone to the same 
level as in the case of saline-treated rats (FIG. 2). 
Comparable observations were also obtained when these experiments were 
analyzed by using SDS-polyacrylamide gel electrophoresis and autoradiography 
(FIG. 3). Similarly, EGTA inhibited phosphorylation in the particulate 
preparation from haloperidol-treated rats more effectively than in those from 
saline-treated rats. Phosphorylation was stimulated proportionally by 0.15 mM 
and 0.25 mM calcium (1.4 x 10 -7 M and 1.1 x 10 -5 M free Ca ++ respectively) in 
both groups of the animals. It is noteworthy that two particular 
phosphoproteins at molecular weight of approximately 40 and 52 kilodaltons were 
markedly stimulated by calcium in comparison to other phosphoproteins (FIG. 3). 
Effect of chronic haloperi~ol treatment on cyclic AMP-dependent 
phosphorylation. Cyclic AMP-dependent phosphorylation was measured in the same 
manner as in the calcium mediated experiments. I mM theophylline was included 
in the assay. 5uM exogenously added cyclic AMP did not further increase 
32p-incorporation in EGTA treated particulate preparations from both saline- 
and haloperidol-treated rats (TABLE II). However, the endogenous cyclic AMP 
level in the haloperidol treated rats, when expressed by the protein kinase 
activity ratio (- cyclic AMP/+ 5uM cyclic AMP) as suggested by Corbin et al. 
(9) on lysine-rich histone f2 (250 ~g) phosphorylation, was significantly 
higher than in the saline-treated rats (TABLE II). 
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FIG. 2 
Dose-response study of calcium on protein phosphorylation in rat 
striatal particulate preparations after chronic treatment with saline 
or haloperidol. The striatal particulate preparations were 
pretreated with 1.2 mM EGTA (0.24 mM assay concentration). Abscissa: 
calculated free calcium concentration (see Methods). Calcium at 
increasing concentrations stimulated 32p-incorporation in 
preparations from both saline- and haloperidol-treated rats. Calcium 
alone, however, did not restore the phosphorylation in the 
preparations from haloperidol-tr~ted rats to the same level ~ i~ 
the saline-treated rats. 
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Effect of chronic saline and haloperidol treatments on calcium 
dependent phosphorylation in rat striatal particulate preparations. 
Autoradiograph and densitogram. A representative result from six 
experiments. Two phosphoproteins (a, b at M.W. 40 and 52 kilodaltons 
respectively) were markedly stimulated by calcium. For other 
details, see Results and Legend for FIG. 2. 
Discussion 
Dopamine receptor supersensitivity and intensified stereotypic behavior 
are generally observed after the chronic administration of neuroleptic drugs 
(10). The drug-induced up-regulation of the dopamine receptor responses has 
been correlated with corresponding increases in various pharmacological and 
neurochemical parameters in the striatum, such as the dopamine receptor binding 
sites (2), dopamine-sensitive adenylate cyclase activity (3) and 
calcium-calmodulin activity (4). In this study, we further demonstrated that 
there is a significant increase of striatal calcium-dependent protein 
phosphorylation in rats chronically treated with haloperidol. Thus, the 
calcium chelating agent (EGTA) inhibited protein phosphorylation more 
effectively in the haloperidol-treated rats than in the saline-treated rats. 
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TABLE II 
Effect of Cyclic AMP (5 uM) on Phosphorylation in the 




pmol/mg protein/2 min 
Saline 
(N=6) 120 ± 14 118 ± 9 
Haloperidol 





-cAMP +cAMP (-cAMP)/(+cAMP) 
pmol/mg protein/2 min 
24 +0.1 34 ±0.1 
33± 0.2 c 37± 0.2 
0.7 ± 0.1 
0]9 ± 0.I c 
aphosphorylation was studied by using endogenous substrate in the absence or 
presence of 5 ~M cyclic AMP. 1.2 mM EGTA-treated particulate preparations 
were used. 5 uM added cyclic AMP did not affect phosphorylation. 
bphosphorylation was performed by using 250 ~g histone f2 as substrate for 
1.2 mM EGTA treated preparations. The values were corrected for endogenous 
phosphorylatio n. 
CSignificantly different from the value for saline-treated rats (P< 0.05). 
When calcium was restored in the preparations, a calcium concentration 
dependent phosphorylation could be obtained in both groups of animals. It 
should be emphasized, nevertheless, that exogenously added calcium alone was 
not sufficient to activate the phosphorylation in particulate preparations from 
haloperidol-treated rats to the same level as seen in the saline-treated rats. 
We have previously reported that haloperidol-treated rats contain a small but 
significant increase (28%) of striatal membrane calmodulin activity (4). We 
have also observed that when the striatal particulate preparation was 
pretreated with EGTA (1.2 mM), this procedure substantially removed the 
endogenous calcium ions and calmodulin (7). Therefore, the greater inhibition 
of calcium-dependent phosphorylation by EGTA in the haloperidol-treated rats as 
shown in this report is expected, due to the reason that EGTA treatment would 
abolish a greater amount of calmodulin activity in the haloperidol-treated rats 
than in the saline-treated rats. Preliminary experiments have indicated that 
addition of authentic calmodulin in the phosphorylation assays potentiated the 
Ca++-dependent phosphorylation in the haloperidol-treated rats to the same 
magnitude as in the saline-treated rats (Lau, unpublished data). 
Calcium and calmodulin have been proposed to play an intimate role in 
neurotransmission through the regulation of neuronal protein phosphorylation 
(11). The results from this study have demonstrated a positive association 
between Ca++-dependent protein phosphorylation and dopamine receptor 
supersensitivity. Furthermore, we also identified that two striatal proteins 
at molecular weight of 40 and 52 kilodaltons are highly phosphorylated in the 
presence of calcium in comparison to other phosphoproteins as revealed by the 
SDS-polyacrylamide gel electrophoresis and autoradiography experiments. These 
proteins may be important in modulating dopamine receptor sensitivity. 
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The total 32p-incorporation in the haloperidol-treated rats was 
significantly higher than in the saline-treated rats. This observation could 
be largely attributed to the elevation of the calcium-kinase activity (as 
discussed above). The possibility remains, however, "that the increase of 
phosphorylation in the chronic haloperidol treated rats may also be resulted 
from a decrease of phosphoprotein phosphatase activity in these animals. The 
activity of this enzyme was not determined in this study. An additional 
explanation for our observations could be due to the activation of adenylate 
cyclase activity (3) and thus the increase of endogenous cyclic AMP levels (as 
represented by the increase of cyclic AMP-dependent protein kinase activit3 
ratio), although the former (calcium) effect was much more pronounced than the 
latter (cyclic AMP) effect. The state of phosphorylation'after chronic saline 
or haloperidol treatment was not affected by exogenously added cyclic AMP. The 
reason for the lack of cyclic AMP-stimulation on phosphorylation by using 
endogenous protein kinase and substrate in this study is not known. It is 
possible that the endogenous substrate for cyclic AMP-dependent protein kinase 
in this preparation is quite different in nature than the histone substrate. 
The possible relationship between the increased calcium-dependent 
phosphorylation and the elevated cyclic AMP content in the chronic 
haloperidol-treated rats requires further investigation. 
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